J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer Oxf Engl, vol.49, issue.6, pp.1374-403, 1990.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, issue.11, pp.2913-2934, 2014.

A. Bittoni, M. Santoni, A. Lanese, C. Pellei, K. Andrikou et al., Neoadjuvant therapy in pancreatic cancer: an emerging strategy, Gastroenterol Res Pract, p.183852, 2014.

S. Cunha, A. Rault, A. Laurent, C. Adhoute, X. Vendrely et al., Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas, J Am Coll Surg, 2005.

C. Partensky and G. Maddern,

, Cancer Radiother J Soc Francaise Radiother Oncol, 1998.

T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, Pancreatic cancer, Lancet Lond Engl, vol.388, pp.73-85, 2016.

P. J. Allen, D. Kuk, C. Castillo, O. Basturk, C. L. Wolfgang et al.,

, Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma, Ann Surg, vol.265, issue.1, pp.185-91, 2017.

Y. S. Chun, T. M. Pawlik, and J. Vauthey, of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers, Ann Surg Oncol, vol.25, issue.4, pp.845-852, 2018.

D. Chatterjee, M. H. Katz, A. Rashid, G. R. Varadhachary, R. A. Wolff et al., Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome, Cancer, vol.118, issue.12, pp.3182-90, 2012.

D. Pietrasz, L. Marthey, M. Wagner, J. Blanc, C. Laurent et al., Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort, Ann Surg Oncol, 2015.

Q. Denost, C. Laurent, J. Adam, M. Capdepont, V. Vendrely et al., Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head, HPB, 2013.

S. Jones, X. Zhang, D. W. Parsons, J. Lin, R. J. Leary et al., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, vol.321, issue.5897, pp.1801-1807, 2008.

J. Kim, H. A. Reber, S. M. Dry, D. Elashoff, S. L. Chen et al., Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins, Gut, vol.55, issue.11, pp.1598-605, 2006.

O. Turrini, M. Gilabert, J. Ewald, V. Moutardier, J. Delpero et al., Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease, J Visc Surg, vol.154, issue.5, pp.329-362, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01789418

M. A. Tempero, M. P. Malafa, S. W. Behrman, A. B. Benson, E. S. Casper et al., Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines, J Natl Compr Cancer Netw JNCCN, vol.12, issue.8, pp.1083-93, 2014.

C. Neuzillet, S. Gaujoux, N. Williet, J. Bachet, L. Bauguion et al., Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up, International Commission on Radiation Units and Measurements, vol.50, issue.12, pp.1257-71, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143547

P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, vol.92, issue.3, pp.205-221, 2000.

D. Dindo, N. Demartines, and P. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, vol.240, issue.2, pp.205-218, 2004.

T. M. Breslin, K. R. Hess, D. B. Harbison, M. E. Jean, K. R. Cleary et al., Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration, Ann Surg Oncol, vol.8, issue.2, pp.123-155, 2001.

H. Golcher, T. Brunner, G. Grabenbauer, S. Merkel, T. Papadopoulos et al., Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, vol.34, issue.7, pp.756-64, 2008.

I. T. Konstantinidis, A. L. Warshaw, J. N. Allen, L. S. Blaszkowsky, C. Castillo et al.,

, Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg, vol.257, pp.731-737, 2013.

J. R. Delpero, P. Bachellier, N. Regenet, L. Treut, Y. P. Paye et al., Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB, vol.16, issue.1, pp.20-33, 2014.

A. G. Morganti, M. Massaccesi, L. Torre, G. Caravatta, L. Piscopo et al., A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer

, Ann Surg Oncol, vol.17, issue.1, pp.194-205, 2010.

K. K. Christians, S. Tsai, A. Mahmoud, P. Ritch, J. P. Thomas et al., Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? The Oncologist, vol.19, pp.266-74, 2014.

T. Hackert, M. Sachsenmaier, U. Hinz, L. Schneider, C. W. Michalski et al.,

, Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients, Ann Surg, vol.264, issue.3, pp.457-63, 2016.

M. Suker, B. R. Beumer, E. Sadot, L. Marthey, J. E. Faris et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol, 2016.

D. Pietrasz, O. Turrini, V. Vendrely, J. Simon, O. Hentic et al., How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort, Ann Surg Oncol, 2019.

J. He, A. B. Blair, V. P. Groot, A. A. Javed, R. A. Burkhart et al., Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?, Ann Surg, vol.268, issue.1, pp.1-8, 2018.

J. M. Cloyd, H. Wang, M. E. Egger, C. Tzeng, L. R. Prakash et al., Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma, JAMA Surg, vol.152, issue.11, pp.1048-56, 2017.

Q. Zhao, A. Rashid, Y. Gong, M. H. Katz, J. E. Lee et al., Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis, Ann Diagn Pathol, vol.16, issue.1, pp.29-37, 2012.

S. M. Lee, M. Katz, L. Liu, M. Sundar, H. Wang et al., Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival, Am J Surg Pathol, vol.40, issue.12, pp.1653-60, 2016.

F. A. Calvo, R. Matute, J. L. García-sabrido, M. Gómez-espí, N. E. Martínez et al., Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome, Am J Clin Oncol, vol.27, issue.4, pp.343-352, 2004.

H. Kourie, E. Auclin, A. S. Cunha, S. Gaujoux, M. Bruzzi et al., Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort, Clin Res Hepatol Gastroenterol, 2019.

B. Vogelstein, K. W. Kinzler, and P. Digital, Proc Natl Acad Sci, vol.96, issue.16, pp.9236-9277, 1999.

J. F. Huggett, S. Cowen, and C. A. Foy, Considerations for digital PCR as an accurate molecular diagnostic tool

, Clin Chem, vol.61, issue.1, pp.79-88, 2015.

B. Bournet, M. Dufresne, J. Selves, J. Torrisani, P. Cordelier et al., Oncogène Kras et cancer du pancréas -Trente ans plus tard. médecine/sciences, vol.29, pp.991-998, 2013.

S. J. Kim, M. Kim, J. Han, Y. Sung, A. S. Lee et al., Prediction of Recurrence With KRAS

, Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma: Pancreas, vol.48, pp.400-411, 2019.

O. Turrini, J. Ewald, L. Barbier, D. Mokart, J. L. Blache et al., Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg, vol.257, pp.726-756, 2013.

H. Riediger, F. Makowiec, E. Fischer, U. Adam, and U. T. Hopt, Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.10, issue.8, pp.1106-1121, 2006.

P. Kim, A. C. Wei, E. G. Atenafu, D. Cavallucci, S. P. Cleary et al., Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma, BJS, vol.100, issue.10, pp.1349-56, 2013.

D. Serment and «. 'hippocrate, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer leurs consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses : que je sois déshonoré et méprisé si j'y manque